

---

**FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY**

---

June 28, 2004

RECEIVED

CENTRAL FAX CENTER

JUN 28 2004

TO: Examiner Maryam Monshipouri  
Group 1652  
571-272-0932FROM: Justin D. Karjala  
Celera Genomics Corp.  
(240) 453-3812FAX NO: (703) 872-9306# OF PAGES (incl. cover): 7

---

Re: U.S. Serial No. 10/697,266, filed October 31, 2003  
Entitled "ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID  
MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES  
THEREOF"  
Atty. Docket No.: CL001099CIPDIV2

A Preliminary Amendment (Restriction Election) and a Fee Sheet (for multiple dependent claims) in the above-identified application follows.

---

*The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL

## for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 290)

**Complete If Known**

Application Number	10/697,266
Filing Date	October 31, 2003
First Named Inventor	Douglas Rusch
Examiner Name	MONSHIPOURI, Maryam
Art Unit	1652
Attorney Docket No.	CL001089 CIP DIV 2

**METHOD OF PAYMENT (check all that apply)**
 Check  Credit card  Money Order  Other  None
 Deposit Account:

Deposit Account Number 50-0970  
Deposit Account Name CELERA GENOMICS

The Director is authorized to: (check all that apply)

 Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.
**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3) (\$)****2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

		Extra Claims	Fee from below	Fee Paid
Total Claims		-20** =	<input type="text"/> X <input type="text"/> =	<input type="text"/>
Independent Claims		- 3** =	<input type="text"/> X <input type="text"/> =	<input type="text"/>
Multiple Dependent			<input type="text"/> =	<input type="text"/> 290 = 290

RECEIVED  
CENTRAL FAX CENTER

JUN 28 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Douglas RUSCH et al.

Serial No.: 10/697,266

Filed: October 31, 2003

For: ISOLATED HUMAN KINASE PROTEINS,  
NUCLEIC ACID MOLECULES ENCODING  
HUMAN KINASE PROTEINS, AND USES  
THEREOF

Art Unit: 1652

Examiner: M. Monshipouri

Atty. Docket: CL001099CIPDIV2

**PRELIMINARY AMENDMENT**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

*By Facsimile*

Sir:

This is in response to an Office Action mailed on May 26, 2004 from Examiner Monshipouri in which a restriction requirement was issued for the above-referenced application.

Applicants hereby elect claim group III (claims 4-6, 8-11, and 22-23, drawn to isolated nucleic acid molecules, vectors, host cells, etc.) for examination and have canceled claims corresponding to the non-elected groups I-II and IV-VIII.

Please amend the application as follows: